Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma

G. Srkalovic, B. Szende, T. W. Redding, K. Groot, Andrew V Schally

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Membrane receptors for D-Trp6-luteinizing hormone-releasing hormone (D-Trp6-LH-RH), somatostatin-14 (SS-14), and insulin-like growth factor I (IGF-I) were estimated in MXT mammary cancers of mice using sensitive multipoint micromethods. The receptors were characterized in untreated animals and following in vivo treatment with microcapsules of the agonist D-Trp6-LH-RH and the somatostatin analog RC-160, which strongly inhibited tumor growth. In the control group, D-Trp6-LH-RH was bound to the single class of saturable, specific, noncooperative receptor sites (K(d) = 29.3 ± 8.48 x 10-9 M; B(max) ± 4.55 = 0.31 pmol/mg membrane protein). Treatment with D-Trp6-LH-RH alone or in combination with RC-160 produced down-regulation of membrane receptors for D-Trp6-LH-RH on MXT mammary tumor cells. RC-160 alone and ovariectomy were without effect on D-Trp6-LH-RH receptors. On the membrane surface of MXT mammary cells, we found one class of high affinity, specific, saturable binding sites for SS-14 (K(d) = 4.4 ± 1.9 x 10-9 M; B(max) = 0.58 ± 0.21 pmol/mg membrane protein). Treatment with RC-160 alone or combined with D-Trp6-LH-RH significantly increased both the dissociation binding constant (K(d) = 18.6 ± 3.5 x 10-9 and 10.1 ± 0.7 x 10-9 M, respectively) and the binding capacity (B(max) = 13.98 ± 1.7 and 21.00 ± 4.0 pmol/mg membrane protein, respectively). We also found specific binding sites (K(d) = 3.01 ± 0.15 x 10-9 M; B(max) = 2.24 ± 0.96 pmol/mg membrane protein) for IGF-I in the membrane fractions of MXT mammary cancers. Chronic treatment with D-Trp6-LH-RH and RC-160 alone or in combination, as well as ovariectomy, significantly decreased the dissociation binding constant of IGF-I membrane receptors on MXT mammary cells. Our results strongly suggest an important role of LH-RH, SS-14, and IGF-I in the growth of MXT mammary carcinoma. Changes in characteristics of receptors after treatment with analogs of LH-RH and SS-14 along with tumor growth inhibition provide additional support for the direct effect of these peptides on tumor cells. A. possible significance of these findings as applied to a clinical environment is discussed.

Original languageEnglish
Pages (from-to)209-218
Number of pages10
JournalProceedings of the Society for Experimental Biology and Medicine
Volume192
Issue number3
StatePublished - Dec 1 1989
Externally publishedYes

Fingerprint

Somatostatin
Insulin-Like Growth Factor I
Gonadotropin-Releasing Hormone
Breast Neoplasms
Tumors
Membranes
Membrane Proteins
Ovariectomy
Breast
Growth
Binding Sites
Cells
LH Receptors
Neoplasms
IGF Type 1 Receptor
Capsules
Animals
Down-Regulation
vapreotide
Control Groups

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. / Srkalovic, G.; Szende, B.; Redding, T. W.; Groot, K.; Schally, Andrew V.

In: Proceedings of the Society for Experimental Biology and Medicine, Vol. 192, No. 3, 01.12.1989, p. 209-218.

Research output: Contribution to journalArticle

@article{d93270eb6bcd424cb114d15dad0715e7,
title = "Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma",
abstract = "Membrane receptors for D-Trp6-luteinizing hormone-releasing hormone (D-Trp6-LH-RH), somatostatin-14 (SS-14), and insulin-like growth factor I (IGF-I) were estimated in MXT mammary cancers of mice using sensitive multipoint micromethods. The receptors were characterized in untreated animals and following in vivo treatment with microcapsules of the agonist D-Trp6-LH-RH and the somatostatin analog RC-160, which strongly inhibited tumor growth. In the control group, D-Trp6-LH-RH was bound to the single class of saturable, specific, noncooperative receptor sites (K(d) = 29.3 ± 8.48 x 10-9 M; B(max) ± 4.55 = 0.31 pmol/mg membrane protein). Treatment with D-Trp6-LH-RH alone or in combination with RC-160 produced down-regulation of membrane receptors for D-Trp6-LH-RH on MXT mammary tumor cells. RC-160 alone and ovariectomy were without effect on D-Trp6-LH-RH receptors. On the membrane surface of MXT mammary cells, we found one class of high affinity, specific, saturable binding sites for SS-14 (K(d) = 4.4 ± 1.9 x 10-9 M; B(max) = 0.58 ± 0.21 pmol/mg membrane protein). Treatment with RC-160 alone or combined with D-Trp6-LH-RH significantly increased both the dissociation binding constant (K(d) = 18.6 ± 3.5 x 10-9 and 10.1 ± 0.7 x 10-9 M, respectively) and the binding capacity (B(max) = 13.98 ± 1.7 and 21.00 ± 4.0 pmol/mg membrane protein, respectively). We also found specific binding sites (K(d) = 3.01 ± 0.15 x 10-9 M; B(max) = 2.24 ± 0.96 pmol/mg membrane protein) for IGF-I in the membrane fractions of MXT mammary cancers. Chronic treatment with D-Trp6-LH-RH and RC-160 alone or in combination, as well as ovariectomy, significantly decreased the dissociation binding constant of IGF-I membrane receptors on MXT mammary cells. Our results strongly suggest an important role of LH-RH, SS-14, and IGF-I in the growth of MXT mammary carcinoma. Changes in characteristics of receptors after treatment with analogs of LH-RH and SS-14 along with tumor growth inhibition provide additional support for the direct effect of these peptides on tumor cells. A. possible significance of these findings as applied to a clinical environment is discussed.",
author = "G. Srkalovic and B. Szende and Redding, {T. W.} and K. Groot and Schally, {Andrew V}",
year = "1989",
month = "12",
day = "1",
language = "English",
volume = "192",
pages = "209--218",
journal = "Experimental Biology and Medicine",
issn = "0037-9727",
publisher = "Society for Experimental Biology and Medicine",
number = "3",

}

TY - JOUR

T1 - Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma

AU - Srkalovic, G.

AU - Szende, B.

AU - Redding, T. W.

AU - Groot, K.

AU - Schally, Andrew V

PY - 1989/12/1

Y1 - 1989/12/1

N2 - Membrane receptors for D-Trp6-luteinizing hormone-releasing hormone (D-Trp6-LH-RH), somatostatin-14 (SS-14), and insulin-like growth factor I (IGF-I) were estimated in MXT mammary cancers of mice using sensitive multipoint micromethods. The receptors were characterized in untreated animals and following in vivo treatment with microcapsules of the agonist D-Trp6-LH-RH and the somatostatin analog RC-160, which strongly inhibited tumor growth. In the control group, D-Trp6-LH-RH was bound to the single class of saturable, specific, noncooperative receptor sites (K(d) = 29.3 ± 8.48 x 10-9 M; B(max) ± 4.55 = 0.31 pmol/mg membrane protein). Treatment with D-Trp6-LH-RH alone or in combination with RC-160 produced down-regulation of membrane receptors for D-Trp6-LH-RH on MXT mammary tumor cells. RC-160 alone and ovariectomy were without effect on D-Trp6-LH-RH receptors. On the membrane surface of MXT mammary cells, we found one class of high affinity, specific, saturable binding sites for SS-14 (K(d) = 4.4 ± 1.9 x 10-9 M; B(max) = 0.58 ± 0.21 pmol/mg membrane protein). Treatment with RC-160 alone or combined with D-Trp6-LH-RH significantly increased both the dissociation binding constant (K(d) = 18.6 ± 3.5 x 10-9 and 10.1 ± 0.7 x 10-9 M, respectively) and the binding capacity (B(max) = 13.98 ± 1.7 and 21.00 ± 4.0 pmol/mg membrane protein, respectively). We also found specific binding sites (K(d) = 3.01 ± 0.15 x 10-9 M; B(max) = 2.24 ± 0.96 pmol/mg membrane protein) for IGF-I in the membrane fractions of MXT mammary cancers. Chronic treatment with D-Trp6-LH-RH and RC-160 alone or in combination, as well as ovariectomy, significantly decreased the dissociation binding constant of IGF-I membrane receptors on MXT mammary cells. Our results strongly suggest an important role of LH-RH, SS-14, and IGF-I in the growth of MXT mammary carcinoma. Changes in characteristics of receptors after treatment with analogs of LH-RH and SS-14 along with tumor growth inhibition provide additional support for the direct effect of these peptides on tumor cells. A. possible significance of these findings as applied to a clinical environment is discussed.

AB - Membrane receptors for D-Trp6-luteinizing hormone-releasing hormone (D-Trp6-LH-RH), somatostatin-14 (SS-14), and insulin-like growth factor I (IGF-I) were estimated in MXT mammary cancers of mice using sensitive multipoint micromethods. The receptors were characterized in untreated animals and following in vivo treatment with microcapsules of the agonist D-Trp6-LH-RH and the somatostatin analog RC-160, which strongly inhibited tumor growth. In the control group, D-Trp6-LH-RH was bound to the single class of saturable, specific, noncooperative receptor sites (K(d) = 29.3 ± 8.48 x 10-9 M; B(max) ± 4.55 = 0.31 pmol/mg membrane protein). Treatment with D-Trp6-LH-RH alone or in combination with RC-160 produced down-regulation of membrane receptors for D-Trp6-LH-RH on MXT mammary tumor cells. RC-160 alone and ovariectomy were without effect on D-Trp6-LH-RH receptors. On the membrane surface of MXT mammary cells, we found one class of high affinity, specific, saturable binding sites for SS-14 (K(d) = 4.4 ± 1.9 x 10-9 M; B(max) = 0.58 ± 0.21 pmol/mg membrane protein). Treatment with RC-160 alone or combined with D-Trp6-LH-RH significantly increased both the dissociation binding constant (K(d) = 18.6 ± 3.5 x 10-9 and 10.1 ± 0.7 x 10-9 M, respectively) and the binding capacity (B(max) = 13.98 ± 1.7 and 21.00 ± 4.0 pmol/mg membrane protein, respectively). We also found specific binding sites (K(d) = 3.01 ± 0.15 x 10-9 M; B(max) = 2.24 ± 0.96 pmol/mg membrane protein) for IGF-I in the membrane fractions of MXT mammary cancers. Chronic treatment with D-Trp6-LH-RH and RC-160 alone or in combination, as well as ovariectomy, significantly decreased the dissociation binding constant of IGF-I membrane receptors on MXT mammary cells. Our results strongly suggest an important role of LH-RH, SS-14, and IGF-I in the growth of MXT mammary carcinoma. Changes in characteristics of receptors after treatment with analogs of LH-RH and SS-14 along with tumor growth inhibition provide additional support for the direct effect of these peptides on tumor cells. A. possible significance of these findings as applied to a clinical environment is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0024854503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024854503&partnerID=8YFLogxK

M3 - Article

C2 - 2574866

AN - SCOPUS:0024854503

VL - 192

SP - 209

EP - 218

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 0037-9727

IS - 3

ER -